title: Role of portal vein embolization in hepatobiliary malignancy.
abstract: OBJECTIVE
  Inadequate remnant liver volume is the major cause of postoperative liver failure. Preoperative portal vein embolization (PVE) is the well accepted procedure to increase future liver remnant (FLR) volume and decrease the incidence of this complication. This study described the author's experience of preoperative PVE at King Chulalongkorn Memorial Hospital since 2002.
  
  
  METHODS
  The clinical data of 29 patients who underwent PVE were reviewed. The FLR volumes before and after the procedure were calculated by CT volumetry. PVE was performed when estimated FLR volume was < 25% in normal liver or < 40% in damaged liver and also when major liver resection combined with major intraabdominal surgery was planned. The complications after PVE and hepatectomy were recorded.
  
  
  RESULTS
  There were no deaths or complications after PVE. The mean growth of FLR was 11%. Power of liver regeneration was suboptimal in old age patients. Sixteen patients underwent liver resection (resectability rate 55.17%). There were 2 cases of postoperative hyperbilirubinemia (12.5%). The hospital mortality rate was 1/16 (6.25%).
  
  
  CONCLUSIONS
  PVE is a useful and safe optional procedure to increase FLR. It not only reduces the postoperative liver failure but also increases the chance of curative resection.
authors.affiliation: Department of Surgery, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. boonchoo5@mailcity.com
authors.forename: Boonchoo
authors.initials: B
authors.lastname: Sirichindakul
authors.forename: Bunthoon
authors.initials: B
authors.lastname: Nonthasoot
authors.forename: Wipusit
authors.initials: W
authors.lastname: Taesombat
authors.forename: Jade
authors.initials: J
authors.lastname: Supaphol
authors.forename: Supanit
authors.initials: S
authors.lastname: Nivatvongs
authors.forename: Akkawat
authors.initials: A
authors.lastname: Janchai
authors.forename: Jarturon
authors.initials: J
authors.lastname: Tantivatana
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001650:Bile Duct Neoplasms / Q000628:therapy*; D001653:Bile Ducts, Intrahepatic; D018281:Cholangiocarcinoma / Q000628:therapy*; D003487:Cyanoacrylates / Q000627:therapeutic use; D004621:Embolization, Therapeutic / Q000379:methods; D004659:Enbucrilate; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D019990:Perioperative Care; D011169:Portal Vein; D012189:Retrospective Studies
chemical_list: D003487:Cyanoacrylates; D004659:Enbucrilate